Raynaud's phenomenon and vitamin D.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of raynaud's, published as a randomized controlled trial.

To their knowledge, there have not been studies to evaluate the effect of vitamin D supplementation on Raynaud's phenomenon (RP).

Why It Was Studied

In the vitamin D group, baseline average blood vitamin D level was 20.9 ng/mL.

VAS 0, VAS 1, and VAS 2 were 58.33, 48.09, and 36.2, respectively.

Who Took Part

The study group was 53 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

In the vitamin D group, baseline average blood vitamin D level was 20.9 ng/mL.

At the end of the study, the average blood vitamin D level was 32.9 ng/mL.

Topics PubMed links to this paper include Dietary Supplements, Raynaud Disease and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 53 patients in people with raynaud's.

The publication is from 2013 (Rheumatology international), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Raynaud's research.